About Mirati Therapeutics (OTCMKTS:MYLGF)
MethylGene, Inc. operates as a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics for cancer and infectious disease.
Industry, Sector and Symbol
Trailing P/E Ratio-86.7142857142857
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Mirati Therapeutics (OTCMKTS:MYLGF) Frequently Asked Questions
What is Mirati Therapeutics' stock symbol?
Mirati Therapeutics trades on the OTCMKTS under the ticker symbol "MYLGF."
Who are some of Mirati Therapeutics' key competitors?
Some companies that are related to Mirati Therapeutics include Bay Banks of Virginia (BAYK), Uacj (UACJF), Corvis Gold (CORVF), BayCom (BCML), Cannabis Sativa (CBDS), Beadell Resources (BDREF), Paringa Resources (PNGZF), Poet Technologies (POETF), MobileSmith (MOST), Carillion (CIOIF), Atlas Iron (AGODY), Power Solutions International (PSIX), Medicure (MCUJF), Peninsula Energy (PENMF), Sundance Energy Australia (SDCJF), Long Run Explorati (WFREF), Essential Energy S (EEYUF) and Singlepoint (SING).
Who are Mirati Therapeutics' key executives?
Mirati Therapeutics' management team includes the folowing people:
- Martin Godbout Ph.D, Chairman of the Board (Age 57)
- Charles M. Baum M.D., Ph.D., President, Chief Executive Officer, Director (Age 55)
- Mark J. Gergen, Chief Operations Officer, Executive Vice President (Age 51)
- Rachel W. Humphrey M.D., Chief Medical Officer, Executive Vice President (Age 51)
- Jamie A. Donadio, Vice President - Finance (Age 38)
- Henry J. Fuchs M.D., Ph.D., Independent Director (Age 55)
- Rodney W. Lappe Ph.D., Independent Director (Age 58)
- Peter A. Thompson M.D., Independent Director (Age 53)
How do I buy Mirati Therapeutics stock?
Shares of Mirati Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mirati Therapeutics' stock price today?
One share of Mirati Therapeutics stock can currently be purchased for approximately $6.07.
How big of a company is Mirati Therapeutics?
Mirati Therapeutics has a market capitalization of $70.20 million.
MarketBeat Community Rating for Mirati Therapeutics (MYLGF)MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Mirati Therapeutics (OTCMKTS:MYLGF) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for Mirati Therapeutics (OTCMKTS:MYLGF)
No earnings announcements for this company have been tracked by MarketBeat.com
Mirati Therapeutics (OTCMKTS:MYLGF) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Mirati Therapeutics (OTCMKTS:MYLGF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Mirati Therapeutics (OTCMKTS MYLGF)
No insider trades for this company have been tracked by MarketBeat.com
Mirati Therapeutics (OTCMKTS MYLGF) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Mirati Therapeutics (OTCMKTS:MYLGF) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Mirati Therapeutics (OTCMKTS MYLGF) Stock Chart for Sunday, February, 25, 2018